We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Opportunity knocks

19 April 2012 By Quentin Webb, Robert Cyran

The British drugmaker is already a partner of Human Genome Sciences and is thus the obvious acquirer. But the U.S. biotech is wise to rebuff a $2.6 bln offer. GSK can take big cost savings, and the bid looks cheap even given scaled-back expectations for the duo’s key product.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)